The Therapeutic Landscape in Chronic Cough
© 2023. The Author(s)..
In recent years, there has been a substantial increase in the development of antitussive therapies and the first new therapy, gefapixant has been licenced in Europe. This review describes current unlicenced treatments for chronic cough and details treatments currently in development for refractory chronic cough and cough in idiopathic pulmonary fibrosis, as well as compounds previously explored.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:202 |
|---|---|
| Enthalten in: |
Lung - 202(2024), 1 vom: 26. Feb., Seite 5-16 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Smith, Jaclyn A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitussive Agents |
|---|
| Anmerkungen: |
Date Completed 27.02.2024 Date Revised 29.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00408-023-00666-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366177958 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366177958 | ||
| 003 | DE-627 | ||
| 005 | 20240229234627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00408-023-00666-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM366177958 | ||
| 035 | |a (NLM)38127133 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Smith, Jaclyn A |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Therapeutic Landscape in Chronic Cough |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2024 | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a In recent years, there has been a substantial increase in the development of antitussive therapies and the first new therapy, gefapixant has been licenced in Europe. This review describes current unlicenced treatments for chronic cough and details treatments currently in development for refractory chronic cough and cough in idiopathic pulmonary fibrosis, as well as compounds previously explored | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antitussives | |
| 650 | 4 | |a Idiopathic pulmonary fibrosis | |
| 650 | 4 | |a P2X3 antagonists | |
| 650 | 4 | |a Refractory chronic cough | |
| 650 | 7 | |a Antitussive Agents |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Lung |d 1976 |g 202(2024), 1 vom: 26. Feb., Seite 5-16 |w (DE-627)NLM000286648 |x 1432-1750 |7 nnns |
| 773 | 1 | 8 | |g volume:202 |g year:2024 |g number:1 |g day:26 |g month:02 |g pages:5-16 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00408-023-00666-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 202 |j 2024 |e 1 |b 26 |c 02 |h 5-16 | ||